Search the Newsreel

Is StandardAero (SARO) Undervalued On Its Earnings Beat?

Tandem Diabetes Care (NASDAQ: TNDM) lifts Q2 sales to $254.6M, trims loss

Tandem Diabetes Care reported strong second-quarter 2026 results, with worldwide sales increasing by 6% to $254.6 million and a significant improvement in gross margin to 57%. The company also narrowed its GAAP net loss to $21.2 million and achieved positive Adjusted EBITDA of $6.4 …

There May Be Underlying Issues With The Quality Of Standex International's (NYSE:SXI) Earnings

Tandem Earnings: Few Surprises as the Firm Makes Progress With Mobi Pump

Jim Cramer Continues To Believe In Banco Santander, S.A. (NYSE:SAN) & European Banks

Standard Engineering Technology profit rises 26.6% in Q1FY27

StandardAero, Inc. (SARO) Tops Q2 Earnings and Revenue Estimates

StandardAero, Inc. (SARO) reported Q2 earnings of $0.4 per share, surpassing the Zacks Consensus Estimate of $0.35, and revenues of $1.6 billion, exceeding estimates by 1.50%. Despite underperforming the S&P 500 year-to-date, the company holds a Zacks Rank #3 (Hold), indicating expected market-aligned performance. …

Is Tandem Diabetes Care Inc (TNDM) a Value Opportunity After Q2 Earnings Miss? GF Score: 66/100

TANDEM DIABETES CARE INC 2026: Revenue $254.56M, EPS ($0.31) — 10-Q Summary

Tandem Diabetes Care Inc. (TNDM) reported its 2026 quarterly results, showing revenue of $254.56 million, an increase from $240.68 million in the previous year. The company significantly reduced its net loss to ($21.17 million) from ($52.4 million) year-over-year, with diluted loss per share narrowing …

Banco Santander, S.A. Sponsored Stock 12‑Month Price Target Raised to $15.27, Implies 4% Upside

Analysts have raised the average 12-month price target for Banco Santander, S.A. Sponsored stock to $15.27, up from $15.19, implying a potential 4% upside from its Aug. 5 closing price. The consensus rating from 24 analysts remains a "Buy," with a majority recommending "Buy" …

Gustavo De Sousa Santos Sells 29,200 Shares of Banco Santander Brasil (NYSE:BSBR) Stock

Gustavo De Sousa Santos, an insider at Banco Santander Brasil (NYSE:BSBR), recently sold 29,200 shares of the company's stock for $166,440, reducing his ownership by over 35%. This transaction comes as the company's stock trades within its 12-month range, offering a 7.2% annualized dividend …

Banco Santander Brasil (NYSE:BSBR) Insider Sells $227,281.80 in Stock

Robson De Souza Rezende, an insider at Banco Santander Brasil (NYSE:BSBR), sold 39,874 shares of the company's stock for $227,281.80, reducing his direct ownership by over 56%. This sale comes amidst weakened analyst sentiment, with recent downgrades leading to an average "Reduce" rating and …

Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say

Compared to Estimates, StandardAero, Inc. (SARO) Q2 Earnings: A Look at Key Metrics

Earnings call transcript: StandardAero lifts 2026 outlook as margins hit record in Q2 2026

StandardAero reported a strong Q2 2026, with revenue up 4.6% to $1.6 billion and adjusted EPS climbing 24% to $0.40, while adjusted EBITDA margin reached a record 14.4%. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, and announced …

Tandem Diabetes Q2 2026 slides: PayGo model drives margin expansion

Tandem Diabetes Care (NASDAQ:TNDM) reported record Q2 2026 sales of $255 million, despite a slight miss on revenue forecasts, driven by a strategic transition to a "PayGo" pharmacy-based reimbursement model. This new model is expected to more than double lifetime revenue per patient and …

Tandem Diabetes’s (NASDAQ:TNDM) Q2 CY2026 Earnings Results: Revenue In Line With Expectations

StandardAero Q2 2026 Earnings: Margin Expansion Supports Higher Guidance

StandardAero (NYSE: SARO) reported strong Q2 2026 results, with revenue up 4.6% to $1.5997 billion and adjusted diluted EPS increasing 24% to $0.40, largely due to margin expansion from productivity gains and contract restructuring. The company's Engine Services segment was a key driver, while …

Standex International rated Hold despite growth in power, data centers, and defense sectors.

Standex International received a Hold rating due to its high valuation at a 31.3x forward P/E, significantly above the sector median. Despite expected mid-to-high single-digit sales growth by FY2027 driven by new products and strong demand in key sectors like power infrastructure, data centers, …

StandardAero Reports Record 14.4% Adjusted EBITDA Margin, Raises 2026 Outlook

StandardAero (NYSE: SARO) announced strong second quarter 2026 results, with revenue up 4.6% to $1,599.7 million and Adjusted Diluted EPS increasing 24% to $0.40. The company achieved a record Adjusted EBITDA Margin of 14.4% and an inflow of $50.2 million in Free Cash Flow, …

California State Teachers Retirement System Acquires 93,976 Shares of StandardAero, Inc. $SARO

The California State Teachers Retirement System significantly increased its stake in StandardAero, Inc. (NYSE:SARO) by 67.6%, acquiring an additional 93,976 shares to hold a total of 232,942 shares valued at approximately $6.0 million. This move comes as StandardAero reported strong quarterly earnings, exceeding analyst …

Standard BioTools Inc. (LAB) Stock Price, News, Quote & History

This article provides comprehensive financial information for Standard BioTools Inc. (LAB), including its current stock price, historical data, and analyst ratings. It details the company's overview, its segments in proteomics and genomics, key products like the SomaScan platform and CyTOF technology, and financial performance …

Standard BioTools Reports Second Quarter 2026 Financial Results

Standard BioTools Inc. announced its financial results for the second quarter of 2026, reporting $20.1 million in revenue and an 84% improvement in adjusted EBITDA year-over-year. The company is progressing with its merger with Treeline Biosciences, anticipated to close before year-end 2026, and has …

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates

Tandem Diabetes Care, Inc. (TNDM) reported a Q2 loss of $0.31 per share, exceeding the Zacks Consensus Estimate of a $0.34 loss, marking an 8.82% surprise. Despite this, the company's Q2 revenues of $254.56 million missed the consensus estimate by 0.1%, leading to an …

Standex International About To Put More Money In Your Pocket (SXI)

Looking at the universe of stocks we cover at Dividend Channel, on 8/7/26, Standex International Corp. (Symbol: SXI) will trade ex-dividend, for its quarterly dividend of $0.34, payable on 8/21/26. As a percentage of SXI's recent stock price of $328.10, this dividend works out …

Standard Chartered: Attractive Exposure To Emerging Markets Despite Higher Loan Loss Provisions

VSTD: Vestand Inc. - Price & Consenus Chart

US Fed clears Santander’s $12.2bn purchase of Webster

Banco Santander has secured approval from the Board of Governors of the Federal Reserve System for its planned purchase of Webster, parent company of Webster Bank in the US. The transaction, worth $12.2bn, was first disclosed in February this year. Based on end-2025 figures, …

Voya Financial (TNDM holder) discloses 149,088 Tandem Diabetes Care shares in 13G/A

Voya Financial, Inc. has filed an amended Schedule 13G/A, disclosing its beneficial ownership of 149,088 shares of Tandem Diabetes Care, Inc. common stock, which represents a 0.2% stake in the company. Voya Financial asserts sole voting and dispositive power over these shares. The filing …

REG - Banco Santander S.A. - Buyback programme: transactions 30Jul-5Aug

Banco Santander S.A. has communicated the transactions carried out under its share buyback program between July 30 and August 5, 2026. The bank repurchased 17,500,000 shares, bringing the total investment in the program to €4,392,508,241, which is approximately 87.3% of the maximum investment. With …

Standard Engineering Technology Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

STANDARD BIOTOOLS INC. Q2 2026: Revenue $20.1M, EPS $(0.07) — 10-Q Summary

STANDARD BIOTOOLS INC. reported its Q2 2026 results, showing revenue of $20.1M and a diluted loss per share of $(0.07), which indicates an improvement compared to the previous year. Key highlights include an announced merger with Treeline Biosciences, the divestiture of the SomaScan business …

StandardAero (NYSE:SARO) Posts Earnings Results, Beats Estimates By $0.08 EPS

Standard Engineering Technology makes Q1FY27 earnings call recording available

StandardAero, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:SARO) 2026-08-06

StandardAero (NYSE: SARO) lifts 2026 outlook after margin gains and Q2 earnings jump